Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The
Respiratory syncytial virus (RSV) has long been a formidable challenge, particularly for infants and older adults. Characterized by cold-like symptoms, RSV can sometimes escalate into severe respiratory conditions necessitating hospitalization. Nearly every child is exposed to RSV by the age of
Gilead Sciences recently announced its decision to withdraw Trodelvy from the market as a treatment for bladder cancer, following disappointing results from its confirmatory TROPiCS-04 clinical trial. This marks a notable shift for a drug that initially showed promise in shrinking tumors and
AbbVie, renowned for its portfolio of groundbreaking treatments, has achieved a major milestone with the FDA's approval of Vyalev, a novel combination therapy aimed at providing extended movement control for patients with advanced Parkinson’s disease. The approval represents more than just a
Sage Therapeutics, a biopharmaceutical company specializing in brain health medications, finds itself at a pivotal moment. Facing financial strains and developmental hurdles, the company is taking significant steps to realign its strategy, including layoffs, leadership changes, and focusing on
In a bold move that underscores its commitment to advancing cancer therapies, Novartis has taken a significant step by investing $70 million upfront in Chengdu Baiyu Pharmaceutical for global rights to a small molecule cancer treatment. This partnership is accompanied by potential milestone
